遠大醫藥(00512.HK)擬1.07億元收購華晨生物80%股權 將打造成全球最好的食品級甘氨酸生產企業
格隆匯10月18日丨遠大醫藥(00512.HK)公吿，集團附屬公司湖北遠大生命科學與技術有限責任公司("遠大生科")近日與河北華陽生物科技有限公司訂立股權收購協議，據此遠大生科將在收購協議約定的相關條件滿足後以人民幣1.072億元收購滄州華晨生物科技有限公司("華晨生物")80%的股權。
華晨生物位於滄州國家級化工園區，是一家從事氨基酸產品研發、生產、銷售及技術服務的公司，其主要產品為甘氨酸及其衍生物，目前公司具備工業級甘氨酸年產3萬噸的生產能力，食用級甘氨酸生產車間正在籌建中。
集團在氨基酸產業領域深耕多年，已經發展成為全球領先的通過生物製造方式規模化生產精品氨基酸產品的企業之一，致力通過生產高品質氨基酸產品服務於生物技術大健康產業，曾獲得國家專精特新企業和省級隱形冠軍企業、國家級知識產權優勢企業等多項榮譽。主要產品包括牛磺酸、半胱氨酸系列、精氨酸系列、酪氨酸系列等氨基酸及衍生化產品20餘種，可廣泛用於醫藥、保健品、食品添加劑、動植物保護等眾多生命領域，核心產品均已通過歐盟、美國、日本、東南亞、中國等多個國家及地區的藥品/食品體系認證。集團氨基酸產業核心產品牛磺酸產能規模目前位居世界第二，半胱氨酸系列產能規模位居世界第一。
此次對於華晨生物的收購，將有望為集團氨基酸產業帶來全新業務增長點，目標將華晨生物打造成全球最好的食品級甘氨酸生產企業；也是集團在精品氨基酸的基礎上，向多元化氨基酸戰略邁進的重要一步，在豐富產品集羣的同時，將氨基酸產業鏈進一步延伸，在上游氨基酸原料及下游終端健康食品及醫藥製劑領域建立深度的產業化及規模化佈局，深度參與全球化高端市場競爭，為集團氨基酸產業領導地位的建立奠定基礎。
集團將在"新技術，高質量，產業鏈，國際化"經營理念引導下加大布局氨基酸產業，持續推進生物製造技術工藝的創新升級與迭代，以治療用氨基酸為基礎、逐步向營養用氨基酸方面延伸，同時向健康類原料及終端製劑類進行拓展，實現大健康領域的全面覆蓋，致力於帶給人類更大健康福祉，堅持“”全球化運營佈局，雙循環經營發展“”策略，形成國內國際雙循環聯動發展並相互促進的新格局，逐步將氨基酸產業打造成集團支柱產業之一。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
